Return to study ST001391 main page
MB Sample ID: SA113274
Local Sample ID: | PTLDS_NYMC_15OYFU |
Subject ID: | SU001465 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Select appropriate tab below to view additional metadata details:
Subject:
Subject ID: | SU001465 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Factors:
Local Sample ID | MB Sample ID | Factor Level ID | Level Value | Factor Name |
---|---|---|---|---|
PTLDS_NYMC_15OYFU | SA113274 | FL014258 | One-year follow-up | Time point |
PTLDS_NYMC_15OYFU | SA113274 | FL014258 | Yes | PTLDS |
Collection:
Collection ID: | CO001460 |
Collection Summary: | Sera (both cohorts) were collected at the time of diagnosis (baseline); at the completion of antibiotic therapy, approximately two to three weeks following diagnosis (post-treatment); and at one-year post-treatment (one-year follow-up). PTLDS (symptoms) patients were classified as such if symptoms developed at or within 6 months following diagnosis and persisted for at least 6 months following the completion of antibiotic therapy. Patients were classified as PTLDS (syndrome) if they met the above criteria and with daily life functional impairment reported. |
Sample Type: | Blood (serum) |
Treatment:
Treatment ID: | TR001480 |
Treatment Summary: | N/A |
Sample Preparation:
Sampleprep ID: | SP001473 |
Sampleprep Summary: | Serum samples were randomized prior to extraction of small molecule metabolites and LC-MS analyses. Metabolites were extracted with 75% methanol as previously described. Extracted metabolites were analyzed by LC-MS. |
Sampleprep Protocol Comments: | doi:10.1038/nprot.2011.335 |
Combined analysis:
Analysis ID | AN002320 |
---|---|
Analysis type | MS |
Chromatography type | Reversed phase |
Chromatography system | Agilent 6520 |
Column | Poroshell 120 EC-C8 (100 x 2.1mm,2.5um) |
MS Type | ESI |
MS instrument type | QTOF |
MS instrument name | Agilent 6520 QTOF |
Ion Mode | POSITIVE |
Units | counts |
Chromatography:
Chromatography ID: | CH001705 |
Instrument Name: | Agilent 6520 |
Column Name: | Poroshell 120 EC-C8 (100 x 2.1mm,2.5um) |
Column Temperature: | 50 |
Flow Gradient: | 2-98% non-linear gradient |
Flow Rate: | 0.25 ml/min |
Solvent A: | 100% water; 0.1% formic acid |
Solvent B: | 100% acetonitrile; 0.1% formic acid |
Chromatography Type: | Reversed phase |
MS:
MS ID: | MS002162 |
Analysis ID: | AN002320 |
Instrument Name: | Agilent 6520 QTOF |
Instrument Type: | QTOF |
MS Type: | ESI |
MS Comments: | LC-MS data were processed with MassHunter Profinder version B.08.00 and Mass Profiler Professional version B.14.9.01 (Agilent Technologies) to identify differentiating molecular features (MFs; metabolites defined by a retention time and accurate mass) between PTLDS and non-PTLDS patients at baseline, post-treatment and one-year follow-up in cohort-one. The biosignature-MFs determined using cohort-one were targeted in patient samples from cohort-two using MassHunter Profinder. |
Ion Mode: | POSITIVE |
Capillary Voltage: | 4000 |
Dry Gas Flow: | 10 l/min |
Dry Gas Temp: | 310 |
Fragment Voltage: | 120 |
Nebulizer: | 45 psi |
Octpole Voltage: | 750 V |